Institutional investors hold a majority ownership of IMGN through the 86.16% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
QS BATTERYMARCH FINANCIAL MANAGE... Bought 70.00 shares of ImmunoGen Inc
APO ASSET MANAGEMENT GMBH Sold 90.0 Thousand shares of ImmunoGen Inc
PRIMECAP MANAGEMENT CO. Sold 2.7 Million shares of ImmunoGen Inc